[Intravenous cibenzoline in the treatment of ventricular and supraventricular arrhythmias].
The efficacy of intravenous cibenzoline in the treatment of supraventricular and ventricular arrhythmias was demonstrated in a French trial of 212 patients including 40 in the acute phase of myocardial infarction. The minimal therapeutic plasma concentration was about 0.3 microgram/ml: this was obtained by a loading dose of 1 mg/kg relayed by a perfusion of 8 mg/kg/24 hours. The clinical tolerance was satisfactory in 96.2% of cases when the contra-indications were respected (severe cardiac failure, intraventricular conduction defects and non-paced 2nd and 3rd degree atrioventricular block). Local tolerance was excellent in all cases.
R
R
Haiat
M F
MF
Aymard
A
A
Dufour
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy* / Q000209:etiology; D004341:Drug Evaluation; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D007263:Infusions, Parenteral; D009203:Myocardial Infarction / Q000150:complications; D013610:Tachycardia / Q000188:drug therapy* / Q000209:etiology
D000889:Anti-Arrhythmia Agents; D007093:Imidazoles; C032151:cifenline
La cibenzoline intraveineuse dans le traitement des troubles du rythme supraventriculaires et ventriculaires.